SCHEMBL16673248

SCHEMBL16673248

CCC(C)OC(=O)C(C)OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.57
ALDH1A1 P00352 4/20 0.46
L3MBTL1 Q9Y468 4/20 0.46
LMNA P02545 1/20 0.46
SLC1A3 P43003 2/20 0.43
SLC1A2 P43004 2/20 0.43
SLC1A1 P43005 2/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
TSHR P16473 2/20 0.42
MAPK1 P28482 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A3 Q01959 1/20 0.41
CTSK P43235 2/20 0.40
CTSL P07711 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16673069 0.86 MAPT (0.49) MAPTALDH1A1L3MBTL1LMNASLC1A3
SCHEMBL28008702 0.85 TSHR (0.54) ALDH1A1L3MBTL1LMNASLC1A3SLC1A2
SCHEMBL16672878 0.85 MAPT (0.55) MAPTALDH1A1L3MBTL1LMNAKMT2A
SCHEMBL7261708 0.84 KMT2A (0.49) ALDH1A1L3MBTL1LMNASLC1A3SLC1A2
SCHEMBL23673195 0.84 KMT2A (0.49) ALDH1A1L3MBTL1LMNASLC1A3SLC1A2
SCHEMBL26674106 0.84 L3MBTL1 (0.43) MAPTALDH1A1L3MBTL1LMNASLC1A3
SCHEMBL30609202 0.84 L3MBTL1 (0.43) MAPTALDH1A1L3MBTL1LMNASLC1A3
SCHEMBL24374486 0.83 ALDH1A1 (0.47) ALDH1A1L3MBTL1LMNASLC1A3SLC1A2
SCHEMBL3813646 0.82 L3MBTL1 (0.64) MAPTALDH1A1L3MBTL1LMNASLC1A3
SCHEMBL10472516 0.82 L3MBTL1 (0.64) MAPTALDH1A1L3MBTL1LMNASLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2869389-B1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME MITSUBISHI CHEM CORP (JP) 2019-11-13 EP disclosed
US-10320030-B2 Nonaqueous electrolyte solution and nonaqueous electrolyte battery employing the same MITSUBISHI CHEMICAL CORPORATION (JP) 2019-06-11 US disclosed
US-20150140448-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2015-05-21 US disclosed
EP-2869389-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME Mitsubishi Chemical Corporation (JP) 2015-05-06 EP disclosed
US-20140107135-A1 PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 AUSPEX PHARMACEUTICALS, INC. (US) 2014-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140107135-A1 PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 PLA2G1B, PLA2G4A, PLA2G4B MAPT 4703/4885ALDH1A1 1423/4885L3MBTL1 3877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.